POMS Corporation Core Values
-
Empower Health Sciences
The products and services we provide enable our customers' success. It allows them to focus on achieving competitive advantage with the products they bring to market, knowing the repeatability and traceability of their manufacturing processes are sound.
-
Partner with Customers for Life
Our focus is on our customers. We bring value through client intimacy and a strong understanding of our industry. Our relationship with our customers extends past basic support and into a singular focus on their overall success. Our products and services are designed to evolve and grow as their business needs do.
-
Foster Quality and Reliability
We understand that software quality and reliability are an extremely important component of our customers' expectations of us. We strive to meet their high standards daily through the strategic mix of process and adaptability. We are craftsmen of our trade and take deep pride in our work.
Our History
1987
Founded as Industrial Computing Designs, Inc. (INCODE)
1997
Reincorporated in Delaware as POMS Corporation
1999
Honeywell Acquires POMS Corporation
2012
Constellation Software Inc. purchases POMS Corporation from Honeywell
2013
Name Changed to POMS Corporation
2024
POMS is 100% Fully Remote Company with Corporate HQ address Redmond, WA
35 Years of Leading Software Development for the Pharmaceutical and Biotech industry
POMS Corporation (formerly INCODE Corporation) was founded in 1987 as the development partner for a consortium of Fortune 100 regulated manufacturing companies. From its inception, the features and capabilities of POMS MES were explicitly designed to meet the stringent requirements for quality and compliance in the cGMP environment.
POMS Corporation was acquired by Honeywell in 1999 and was then acquired by Constellation Software Incorporated (ticker symbol CSU.TO listed on the Toronto Stock Exchange) in 2012. Throughout the changes in ownership, POMS Corporation has remained intact as the same company was initially founded and has retained many of the same employees who began the company.
Meet the Leadership Team
The POMS Corporation management team brings together extensive world-class experience in Life Sciences, FDA Regulation, and Software Technology. The company's core team has an excellent knowledge base and expertise in designing and implementing MES projects ranging from standard out-of-the-box solutions to complex, fully integrated implementations.
Acquisition by Constellation Software Inc.
In 2012, POMS Corporation was acquired by Constellation Software Inc.'s Perseus Operating Group. As part of the Constellation family, POMS continues to provide the specialized and individual attention you expect from an innovative software company in the regulated life sciences industries.
With headquarters in Toronto, Canada, and offices in North America, Europe, Australia, South America, and Africa, we have over 22,000 employees generating consolidated revenues exceeding US $6.6 billion.
Constellation Software Inc., is listed on the Toronto Stock Exchange under CSU.TO ticker symbol.
Awards and Certificates
2019
The customer service department of the year-computer software - up to l00 employees
2020
Achieving Business Agility with the Scaled Agile Framework
2018Peer voted conference award for automatically validated recipe authoring.
"The platform (POMSnet) is very easy to learn and understand. The help and support team is quite good and helping with all parts of the project which is really commendable."
Gartner Peer Insights Review
Project Manager Data and Analytics
$3 Billion Company
POMS Announces the Release of POMSnet R500.3 End-to-End HTML5 UI
December 5, 2019Join POMS at Phacilitate in Miami 2020
January 24, 2020
Latest News
Subscribe to our newsletter to receive the latest announcements about POMS Corporation, News, and Updates
MES BLOG
Key Life Sciences MES Selection CriteriaAugust 6, 2024 - 3:49 PM
Pharma MES Berlin 2024July 26, 2024 - 6:15 PM
POMS Corporation Sponsors ISPE Biotechnology Conference 2024June 15, 2024 - 3:59 PM
Enabling Cell and Gene Therapy Start Ups to Thrive and DeliverMarch 1, 2019 - 10:20 AM